The arrival of the Retatru vial represents a potential shift in the landscape to body control . This innovative medication combines two mechanisms – agonist of the GLP-1 receptor and blocking of the DPP-4 enzyme – offering a unique method for addressing excess weight . Early clinical data demonstrate promising efficacy in promoting considerable